Loading patent…
AssigneeAmgen Fremont Inc.
InventorsJohn S. Babcook, Jaspal S. Kang, Orit Foord, Larry Green, Xiao Feng, Scott Klakamp, Mary Haak-Frendscho, Palaniswami Rathanaswami, Craig Pigott, Meina Liang, Yen-Wah "Rozanne" Lee, Kathy Manchulenko, Raffaella Faggioni, Giorgio Senaldi, Qiaojuan Jane Su
Estimating the term…
Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α and comprises a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence of “Ser Tyr Asp Met His”.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α and comprises a light chain complementarity determining region 1 (CDR1) having an amino acid sequence of “Arg Ala Ser Gln Gly Ile Arg Ile Asp Leu Gly”.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α and comprises VH3-33 heavy chain gene, or conservative variant thereof.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α, wherein antibody comprises a heavy chain complementarity determining region 1 (CDR1) corresponding to canonical class 1.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α and comprises a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence of “Arg Asn Tyr Met Ser”.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α and comprises a light chain complementarity determining region 1 (CDR1) having an amino acid sequence of “Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala”.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α and comprises VH3-53 heavy chain gene, or conservative variant thereof.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α, wherein antibody comprises a heavy chain complementarity determining region 1 (CDR1) corresponding to canonical class 1.
A human monoclonal antibody that specifically binds to Tumor Necrosis Factor-α and comprises a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence selected from the group consisting of “Ser Tyr Gly Met His,” “Ser Tyr Asp Met His,” “Asn Tyr Asp Met His,” “Asn Tyr Asp Met His,” “Asn Tyr Asp Ile His,” “Ser Tyr Asp Ile His,” “Ser Asn Tyr Met Ser,” “Arg Asn Tyr Met Ser,” “Ser Tyr Gly Met His,” “Asn Tyr Gly Ile His,” “Asn Tyr Gly Met His,” “Ser Tyr Tyr Trp Ser,” “His Tyr Tyr Trp Ser,” and “Ser Gly Gly Tyr Tyr Trp Ser.”
Dependencies are inferred from the claim text.